VIRxSYS Presents HIV Vaccine Data at 2010 International AIDS Conference

VIRxSYS Presents HIV Vaccine Data at 2010 International AIDS Conference

VIENNA, AUSTRIA and GAITHERSBURG, MD - July 22, 2010 - VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, today reported updated data from the Company's HIV vaccine study as an invited presenter during the National Association of People with AIDS (NAPWA) and The AIDS Institute's Community Forum at the XVIII International AIDS Conference 2010 in Vienna, Austria. 
 
"We are honored to share the results of our study at the International AIDS Conference," said VIRxSYS President and CEO Riku Rautsola, Ph.D.  "This event is a great opportunity for thought leaders from around the world to collaborate on a solution to HIV/AIDS, and we hope that the results from our study will be a valued contribution."
 
The data demonstrates that the VIRxSYS vaccine VRX1273 is capable of achieving significant control of viral load over the course of four months following a challenge with a highly pathogenic simian immunodeficiency virus (SIV), a virus found in non-human primates and similar to HIV. In addition, monkeys vaccinated with VRX1273 demonstrated an improved immune response. Importantly, no adverse reactions have been observed in any of the vaccinated animals following multiple infusions of the lentiviral vaccine. The data reported today updates results originally presented at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.  VIRxSYS is currently preparing an Investigational New Drug Application for the therapeutic use of their HIV vaccine candidate in HIV infected patients. 
 
Also presented at the event was data on Lexgenleucel-T (VRX496), the Company's investigational gene-modified cellular therapy product for the treatment of HIV. Phase 2 studies of Lexgenleucel-T in 65 HIV positive subjects, including 48 who had failed drug regimens and had limited treatment options remaining, showed infusions of the product to be safe and well tolerated. The Company is working with the NIAID/NIH AIDS Clinical Trial Group (ACTG) on the design and planning for an additional Phase 2 study (Protocol A5291), expected to commence in 2011. 
 
About VIRxSYS
Founded in 1998, VIRxSYS is a private biotechnology company that focuses on the development of novel lentiviral gene delivery platform and RNA technologies for the treatment of serious diseases. The Company has exclusively licensed its patented, proprietary lentiviral technology platform from The Johns Hopkins University (JHU) in Baltimore, Maryland, and obtained its SMaRTTM technology from Intronn Inc. More information regarding VIRxSYS can be found at www.virxsys.com.
 
 
Stephanie Hughes Koenig
Account Supervisor
Corinth Group Communications
Email: [email protected]

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.